Carboplatin is a second-generation platinum analogue with reduced nephrotoxicity compared to cisplatin. It is used in various chemotherapeutic regimens as monotherapy or in combination.
Recommended for:
Ovarian cancer (initial and recurrent)
Non-small cell lung cancer
Head and neck tumours
Patients requiring a gentler platinum therapy
Used in the treatment of epithelial ovarian cancer, non-small cell lung cancer, and malignancies of the head and neck. Administered alone or in combination with other agents.
Administered via intravenous infusion under medical supervision. Dosing is calculated based on body surface area and renal function. Adequate hydration and supportive care may be required.
Contraindications:
Hypersensitivity to carboplatin or other platinum compounds
Severe bone marrow suppression
Significant renal impairment
Pregnancy and breastfeeding
Side Effects:
Bone marrow suppression (leukopenia, anemia, thrombocytopenia)
Nausea and vomiting
Renal and hepatic dysfunction
Hearing disorders (ototoxicity)
Allergic reactions (rash, bronchospasm, anaphylaxis)
